Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27480675 | 0.93 | — | — | |
| SCHEMBL10145509 | 0.93 | — | — | |
| SCHEMBL19285193 | 0.82 | — | — | |
| SCHEMBL23064592 | 0.79 | SLC18A3 (0.36) | UGT2B7SLC6A4SLC6A3GAAALDH1A1 | |
| SCHEMBL580451 | 0.79 | UGT2B7 (0.44) | UGT2B7GAAIDO1TDO2 | |
| SCHEMBL6557170 | 0.78 | GAA (0.32) | GAAIDO1TDO2 | |
| SCHEMBL10901618 | 0.77 | SLC6A4 (0.35) | SLC6A4SLC6A3 | |
| SCHEMBL7652118 | 0.76 | GAA (0.31) | GAAIDO1TDO2 | |
| SCHEMBL15540957 | 0.76 | GAA (0.31) | SLC6A4SLC6A3GAAIDO1TDO2 | |
| SCHEMBL20548668 | 0.76 | GAA (0.31) | GAAIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2720539-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
| CN-103917093-B | Opsin binding ligands, compositions, and methods of use | 比卡姆药品公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-106431988-A | Opsin-binding ligands, compositions and methods of use | 比卡姆药品公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9457004-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150366834-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9133082-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2785178-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| CN-103917093-A | Opsin binding ligands, compositions, and methods of use | BIKAM PHARMACEUTICALS INC | 2014-07-09 | — | — | CN | disclosed |
| US-20140135374-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2720539-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2013081642-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2012174064-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135374-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | UGT2B7 3156/4885SLC6A4 3379/4885SLC6A3 1635/4885 |
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | UGT2B7 3419/4885SLC6A4 3531/4885SLC6A3 1696/4885 |
| US-20150366834-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | UGT2B7 3156/4885SLC6A4 3379/4885SLC6A3 1635/4885 |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | CRYAB, CRYAA, PDE6C | UGT2B7 3274/4885SLC6A4 3449/4885SLC6A3 1638/4885 |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, PDE6C | UGT2B7 3419/4885SLC6A4 3531/4885SLC6A3 1696/4885 |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | UGT2B7 3419/4885SLC6A4 3531/4885SLC6A3 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.